Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis

Summary

This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, PK, PD and immumogenicity of GR1802 injection in comparison to placebo in patients with atopic dermatitis. Patients will receive GR1802 injection or Placebo every 2 Weeks.

Timeline

Start

2024-01

Primary completion

2025-06

Completion

2026-01

Drugs

Indications